MacroGenics Consensus Price Target Rises 12% to $9.52
The average one-year price target for MacroGenics (NASDAQGS:MGNX) has been revised to $9.52 / share. This is an increase of 12.00% from the prior estimate of $8.50 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute an investment recommendation by Fintel. The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $11.55 / share. The average price target represents an increase of 138.00% from the latest reported closing price of $4.00 / share, as of September 11, 2026.
The consensus target has experienced consecutive increases, with a count of 2 consecutive upward revisions. Looking at the target history, the mean target was $6.88 on June 30, 2026, and August 4, 2026, before rising to $8.50 on August 28, 2026, and reaching $9.52 as of September 14, 2026. This represents a target change of +38.27% since the 90-day baseline date of June 9, 2026. Over the observed twelve-month period, the mean target reached a high of $9.52 on September 14, 2026, and a low of $3.47 on February 25, 2026. The median target rose to $11.22 from $8.16, representing an absolute median change of $3.06. Meanwhile, the target range width remained unchanged at $5.49, with a target range width change of 0.00%. The current gap between the mean and median targets stands at $1.70.
In terms of price performance, MacroGenics shares experienced a one-week price change of -9.09% from a baseline close of $4.40 on September 4, 2026. Over a one-month period, the price changed by +2.04% from a baseline close of $3.92 on August 11, 2026. The company's latest earnings report, released on August 13, 2026, showed an actual EPS of -0.26 compared to an estimated EPS of -0.1283. Revenue for the quarter was $32,832,000.00, which was below the estimated $68,804,865.00, representing a revenue surprise of -52.28%. On August 17, 2026, B. Riley Securities maintained its Buy rating on the stock. The recommendation trend as of September 1, 2026, shows 3 strong buy, 6 buy, and 5 hold recommendations, totaling 14 recommendations, with 64.3% positive and 35.7% hold. This compares to August 1, 2026, when there were 3 strong buy, 5 buy, and 5 hold recommendations, totaling 13 recommendations.
MacroGenics is a US-headquartered biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for cancer and other severe diseases. It utilizes proprietary platforms like DART® and TRIDENT™ and has developed margetuximab, approved under the name Margenza. Within the broader GICS Biotechnology sub-industry, which covers 25 companies, analyst actions have been mixed: 10 companies had targets raised, 11 were lowered, and 4 remained unchanged. The sub-industry median target revision percent was 0.00%, with a median implied change of +116.75%.
Several peers in the biotechnology space also saw target updates. Zymeworks and Xencor both received upward target revisions, while Sutro Biopharma experienced a slight downward revision.
| Company Name | Target revision | Implied change |
|---|---|---|
| Zymeworks | +5.72% | +61.64% |
| Sutro Biopharma | -1.09% | +185.74% |
| Xencor | +1.55% | +26.88% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.